Cargando…
What Have We Learnt about BCG Vaccination in the Last 20 Years?
A number of new tuberculosis (TB) vaccines have been or are entering clinical trials, which include genetically modified mycobacteria, mycobacterial antigens delivered by viral vectors, or mycobacterial antigens in adjuvant. Some of these vaccines aim to replace the existing BCG vaccine but others w...
Autores principales: | Dockrell, Hazel M., Smith, Steven G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601272/ https://www.ncbi.nlm.nih.gov/pubmed/28955344 http://dx.doi.org/10.3389/fimmu.2017.01134 |
Ejemplares similares
-
Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?
por: Dockrell, Hazel M., et al.
Publicado: (2022) -
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
por: Marshall, Michael J. E., et al.
Publicado: (2017) -
Research into Neospora caninum—What Have We Learnt in the Last Thirty Years?
por: Reichel, Michael P., et al.
Publicado: (2020) -
Ultrasound Imaging in Psoriatic Arthritis: What Have We Learnt in the Last Five Years?
por: Dubash, Sayam R., et al.
Publicado: (2020) -
What have we learnt from Covid?
por: Salter, Mark Steven
Publicado: (2021)